Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China

Background: Fulvestrant 500mg has proved its clinical effectiveness in previous trials as primary or second line treatment of hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2˗) post-menopausal advanced breast cancer. This real-world study aimed to investigate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Wen, Li, Huiping, Song, Guohong, Zhang, Ruyan, Ran, Ran, Yan, Ying, Di, Lijun, Jiang, Hanfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545684/
https://www.ncbi.nlm.nih.gov/pubmed/33046982
http://dx.doi.org/10.7150/jca.47960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545684/
https://www.ncbi.nlm.nih.gov/pubmed/33046982
http://dx.doi.org/10.7150/jca.47960

Ejemplares similares